Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 200 shares, a decline of 83.3% from the October 31st total of 1,200 shares. Based on an average trading volume of 28,700 shares, the days-to-cover ratio is presently 0.0 days.
Wall Street Analyst Weigh In
NVZMY has been the subject of several analyst reports. Citigroup downgraded shares of Novozymes A/S from a “neutral” rating to a “sell” rating in a report on Thursday, October 17th. Barclays raised shares of Novozymes A/S to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Berenberg Bank raised Novozymes A/S to a “strong-buy” rating in a report on Tuesday, September 24th.
Check Out Our Latest Research Report on NVZMY
Novozymes A/S Trading Up 0.2 %
Novozymes A/S Cuts Dividend
The business also recently announced a dividend, which was paid on Wednesday, September 18th. Stockholders of record on Monday, September 9th were given a dividend of $0.1678 per share. The ex-dividend date of this dividend was Monday, September 9th. Novozymes A/S’s dividend payout ratio is currently 41.77%.
Novozymes A/S Company Profile
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
See Also
- Five stocks we like better than Novozymes A/S
- How Can Investors Benefit From After-Hours Trading
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Start Investing in Real Estate
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Airline Stocks – Top Airline Stocks to Buy Now
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.